Abstract
Increasing evidences support the notion that the impairment of intracellular degradative machinery is responsible for the accumulation of oxidized/misfolded proteins that ultimately results in the deposition of protein aggregates. These events are key pathological aspects of “protein misfolding diseases”, including Alzheimer disease (AD). Interestingly, Down syndrome (DS) neuropathology shares many features with AD, such as the deposition of both amyloid plaques and neurofibrillary tangles. Studies from our group and others demonstrated, in DS brain, the dysfunction of both proteasome and autophagy degradative systems, coupled with increased oxidative damage. Further, we observed the aberrant increase of mTOR signaling and of its down-stream pathways in both DS brain and in Ts65Dn mice.
Based on these findings, we support the ability of intranasal rapamycin treatment (InRapa) to restore mTOR pathway but also to restrain oxidative stress resulting in the decreased accumulation of lipoxidized proteins. By proteomics approach, we were able to identify specific proteins that showed decreased levels of HNE-modification after InRapa treatment compared with vehicle group. Among MS-identified proteins, we found that reduced oxidation of arginase-1 (ARG-1) and protein phosphatase 2A (PP2A) might play a key role in reducing brain damage associated with synaptic transmission failure and tau hyperphosphorylation. InRapa treatment, by reducing ARG-1 protein-bound HNE levels, rescues its enzyme activity and conceivably contribute to the recovery of arginase-regulated functions. Further, it was shown that PP2A inhibition induces tau hyperphosphorylation and spatial memory deficits. Our data suggest that InRapa was able to rescue PP2A activity as suggested by reduced p-tau levels.
In summary, considering that mTOR pathway is a central hub of multiple intracellular signaling, we propose that InRapa treatment is able to lower the lipoxidation-mediated damage to proteins, thus representing a valuable therapeutic strategy to reduce the early development of AD pathology in DS population.
Document Type
Article
Publication Date
3-9-2019
Digital Object Identifier (DOI)
https://doi.org/10.1016/j.redox.2019.101162
Funding Information
This work was supported by the Ministry of Instruction, Universities and Research (MIUR) under the SIR program n° RBSI144MT to FDD, Jerome Lejeune Foundation with the grant # PERLUIGI/1484-PM2016A to MP and Fondi di Ateneo Progetti Grandi # RG116154C9214D1A from Sapienza University of Rome to FDD.
Related Content
Supplementary data to this article can be found online at https://doi.org/10.1016/j.redox.2019.101162.
Repository Citation
Di Domenico, Fabio; Tramutola, Antonella; Barone, Eugenio; Lanzillotta, Chiara; Defever, Olivia; Arena, Andrea; Zuliani, Ilaria; Foppoli, Cesira; Iavarone, Federica; Vincenzoni, Federica; Castagnola, Massimo; Butterfield, D. Allan; and Perluigi, Marzia, "Restoration of Aberrant mTOR Signaling by Intranasal Rapamycin Reduces Oxidative Damage: Focus on HNE-Modified Proteins in a Mouse Model of Down Syndrome" (2019). Chemistry Faculty Publications. 161.
https://uknowledge.uky.edu/chemistry_facpub/161
Multimedia component 1.
1-s2.0-S2213231718310103-mmc2.pptx (2600 kB)
Multimedia component 2.
1-s2.0-S2213231718310103-mmc3.pptx (308 kB)
Multimedia component 3.
Notes/Citation Information
To be published in Redox Biology.
© 2019 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).